StockMacro
Menu

Precision BioSciences

$7.40 -2.4% in 6 monthsMarket cap $282.5M

DTIL on XNAS, Health Care, Precision BioSciences, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue jumped 6353% to $45M and the stock gained 49% in a year, though it lost $38.5M.

  • GoodInstitutional holders rose 14%, from 95 filers to 108

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
69
Website
precisionbiosciences.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $7.6M.
Quarter to 31 Dec 2021: revenue $6.3M, net income -$22.3MQuarter to 31 Dec 2021: revenue $6.3M, net income -$22.3MQuarter to 31 Mar 2022: revenue $3.3M, net income -$28.2MQuarter to 31 Mar 2022: revenue $3.3M, net income -$28.2MQuarter to 30 Jun 2022: revenue $3.8M, net income -$31.0MQuarter to 30 Jun 2022: revenue $3.8M, net income -$31.0MQuarter to 30 Sep 2022: revenue $7.4M, net income -$23.9MQuarter to 30 Sep 2022: revenue $7.4M, net income -$23.9MQuarter to 31 Dec 2022: revenue $10.6M, net income -$28.5MQuarter to 31 Dec 2022: revenue $10.6M, net income -$28.5MQuarter to 31 Mar 2023: revenue $8.8M, net income -$25.1MQuarter to 31 Mar 2023: revenue $8.8M, net income -$25.1MQuarter to 30 Jun 2023: revenue $19.8M, net income -$11.9MQuarter to 30 Jun 2023: revenue $19.8M, net income -$11.9MQuarter to 30 Sep 2023: revenue $13.1M, net income -$8.1MQuarter to 30 Sep 2023: revenue $13.1M, net income -$8.1MQuarter to 31 Dec 2023: revenue $7.0M, net income -$16.3MQuarter to 31 Dec 2023: revenue $7.0M, net income -$16.3MQuarter to 31 Mar 2024: revenue $17.6M, net income $8.6MQuarter to 31 Mar 2024: revenue $17.6M, net income $8.6MQuarter to 30 Jun 2024: revenue $49.9M, net income $32.7MQuarter to 30 Jun 2024: revenue $49.9M, net income $32.7MQuarter to 30 Sep 2024: revenue $576K, net income -$16.4MQuarter to 30 Sep 2024: revenue $576K, net income -$16.4MQuarter to 31 Dec 2024: revenue –, net income -$17.7MQuarter to 31 Mar 2025: revenue $29K, net income -$20.6MQuarter to 31 Mar 2025: revenue $29K, net income -$20.6MQuarter to 30 Jun 2025: revenue $18K, net income -$23.5MQuarter to 30 Jun 2025: revenue $18K, net income -$23.5MQuarter to 30 Sep 2025: revenue $13K, net income -$21.8MQuarter to 30 Sep 2025: revenue $13K, net income -$21.8MQuarter to 31 Dec 2025: revenue $34.2M, net income $20.1MQuarter to 31 Dec 2025: revenue $34.2M, net income $20.1MQuarter to 31 Mar 2026: revenue $10.8M, net income -$18.4MQuarter to 31 Mar 2026: revenue $10.8M, net income -$18.4MQuarter to 30 Jun 2026: revenue $0, net income -$32.7MQuarter to 30 Jun 2026: revenue $0, net income -$32.7MQuarter to 30 Sep 2026: revenue $0, net income -$7.6MQuarter to 30 Sep 2026: revenue $0, net income -$7.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $49.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$7.6M
30 Jun 2026$0-$32.7M
31 Mar 2026$10.8M-$18.4M
31 Dec 2025$34.2M$20.1M
30 Sep 2025$13K-$21.8M
30 Jun 2025$18K-$23.5M
31 Mar 2025$29K-$20.6M
31 Dec 2024–-$17.7M
30 Sep 2024$576K-$16.4M
30 Jun 2024$49.9M$32.7M
31 Mar 2024$17.6M$8.6M
31 Dec 2023$7.0M-$16.3M
30 Sep 2023$13.1M-$8.1M
30 Jun 2023$19.8M-$11.9M
31 Mar 2023$8.8M-$25.1M
31 Dec 2022$10.6M-$28.5M
30 Sep 2022$7.4M-$23.9M
30 Jun 2022$3.8M-$31.0M
31 Mar 2022$3.3M-$28.2M
31 Dec 2021$6.3M-$22.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $45.0M $698K
Revenue growthRevenue of the last 12 months compared with the 12 months before. +6353% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$38.5M -$83.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -80.3% – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -85.6% – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -113% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $81.8M $44.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $22.4M $22.4M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$59.4M (net cash) -$22.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.43 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.85
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 6.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.0 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Precision BioSciencesDTIL (this company) $282.5Mloss6.3+6353%-85.6%
AgenusAGEN $270.1M8.82.0+25%23.0%
Kyverna TherapeuticsKYTX $269.3Mloss–––
TRex BioTRXB $297.0M––––
OcugenOCGN $260.6Mloss54.5-11%–
X4 PharmaceuticalsXFOR $306.3Mloss18.1-50%-475%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$2K

bought $30K, sold $28K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

108 13F filers vs 95

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

70%

19.5M shares held by 13F filers (30 Sep 2026) of 27.9M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

7.5%

2.1M shares sold short (30 Oct 2026) of 27.9M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.5

2.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-11%

2.4M shares sold short in the report before, 2.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

74%

74% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 51%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

15×

15 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 2.4M, 2.0× a year earlier

Price $7.40 on 20 Nov 2026, +49% over 12 months (12-month range $3.57 to $10.60)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $396K in the last 12 months (the 12 months before: -$213K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $18K in the latest quarter, -72% on a year earlier.
Institutional holders (13F filers). 108 13F filers reported holding it in the latest 13F quarter, +100% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
1 Sep 2026Sharp changeShort interest spike: short interest spike, 2.4M vs usual 1.3M (2026-08-14); 2.0x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.3M (2026-07-31); 2.3x the same period a year earlier
27 Jul 20268-K and other filingsDirector or officer change
26 May 20268-K and other filingsDirector or officer change
26 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 2026Sharp changeQuarterly revenue change: quarterly revenue change, 10.8M vs usual 607K (2026-03-31); 373.7x the same period a year earlier
19 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 34.2M vs usual 607K (2025-12-31); 53.6x the same period a year earlier
2 Sep 20258-K and other filingsDirector or officer change
2 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 May 2025Sharp changeShort interest spike: short interest spike, 667K vs usual 302K (2025-04-30); 2.0x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 652K vs usual 302K (2025-04-15); 1.9x the same period a year earlier
15 Apr 2025Sharp changeShort interest spike: short interest spike, 753K vs usual 293K (2025-03-31); 2.6x the same period a year earlier
1 Apr 2025Sharp changeShort interest spike: short interest spike, 618K vs usual 282K (2025-03-14); 3.5x the same period a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 737K vs usual 275K (2025-02-28); 15.1x the same period a year earlier
7 Mar 20258-K and other filingsDirector or officer change
4 Mar 2025Sharp changeShort interest spike: short interest spike, 775K vs usual 272K (2025-02-14); 19.5x the same period a year earlier
18 Feb 2025Sharp changeShort interest spike: short interest spike, 757K vs usual 272K (2025-01-31); 0.5x the same period a year earlier
29 Jan 20258-K and other filingsDirector or officer change
29 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jan 2025Sharp changeShort interest spike: short interest spike, 912K vs usual 272K (2025-01-15); 0.4x the same period a year earlier
12 Sep 20248-K and other filingsDirector or officer change
12 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 49.9M vs usual 9.7M (2024-06-30); 2.5x the same period a year earlier
10 Jun 20248-K and other filingsDirector or officer change
10 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Apr 20248-K and other filingsA major agreement ended
30 Jan 2024Sharp changeShort interest spike: short interest spike, 2.2M vs usual 842K (2024-01-12); 2.3x the same period a year earlier
23 Jan 20248-K and other filingsDirector or officer change
23 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Oct 20238-K and other filingsDelisting notice or listing transfer
7 Sep 20238-K and other filingsDirector or officer change
7 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 20238-K and other filingsCompleted an acquisition or asset sale
28 Apr 20238-K and other filingsDelisting notice or listing transfer
24 Feb 20238-K and other filingsDirector or officer change
24 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Nov 20228-K and other filingsDirector or officer change
2 Sep 20228-K and other filingsDirector or officer change
2 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jul 2022Sharp changeShort interest spike: short interest spike, 5.4M vs usual 2.4M (2022-06-30); 1.7x the same period a year earlier
31 May 20228-K and other filingsDirector or officer change
31 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: $51K published
Month from 1 Apr 2022: -$16K published
Month from 1 Jun 2022: -$8K published
Month from 1 Sep 2022: $60K published
Month from 1 Oct 2022: -$15K published
Month from 1 Mar 2023: -$44K published
Month from 1 Apr 2023: -$6K published
Month from 1 Jun 2023: -$10K published
Month from 1 Nov 2023: -$56K published
Month from 1 Jan 2024: -$75K published
Month from 1 May 2024: -$26K published
Month from 1 Jun 2024: -$2K published
Month from 1 Nov 2024: -$9K published
Month from 1 Dec 2024: $14K published
Month from 1 Jan 2025: -$217K published
Month from 1 Mar 2025: $40K published
Month from 1 Jun 2025: $28K published
Month from 1 Jul 2025: -$63K published
Month from 1 Sep 2025: $7K published
Month from 1 Oct 2025: $13K published
Month from 1 Nov 2025: -$35K published
Month from 1 Dec 2025: $34K published
Month from 1 Jan 2026: -$283K published
Month from 1 Feb 2026: -$148K published
Month from 1 Sep 2026: $24K published
Month from 1 Oct 2026: $6K published
Month from 1 Nov 2026: -$28K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Oct 2025: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $6.3M, -28% on a year earlier; public on 16 Mar 2022
Quarter ended 31 Mar 2022: $3.3M, -80% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $3.8M, -94% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $7.4M, -69% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $10.6M, +67% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $8.8M, +165% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $19.8M, +418% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $13.1M, +78% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $7.0M, -34% on a year earlier; public on 28 Mar 2024
Quarter ended 31 Mar 2024: $17.6M, +100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $49.9M, +152% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $576K, -96% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Mar 2025: $29K, -100% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $18K, -100% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $13K, -98% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $34.2M; public on 13 Mar 2026
Quarter ended 31 Mar 2026: $10.8M, +37272% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $1.5M, +37% on a year earlier; public on 16 Mar 2022
Quarter ended 31 Mar 2022: $818K, -27% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $779K, -54% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $1.1M, +49% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $632K, -58% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $521K, -36% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $1.1M, +38% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $386K, -65% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $86K, -83% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $28K, -97% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $39K, -90% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $97K; public on 27 Mar 2025
Quarter ended 31 Mar 2025: $64K, -26% on a year earlier; public on 16 May 2025
Quarter ended 31 Dec 2025: $19K, -80% on a year earlier; public on 13 Mar 2026
Quarter ended 31 Mar 2026: $18K, -72% on a year earlier; public on 6 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 123; public on 14 Feb 2022
31 Mar 2022 report: 144; public on 16 May 2022
30 Jun 2022 report: 115; public on 15 Aug 2022
30 Sep 2022 report: 96; public on 14 Nov 2022
31 Dec 2022 report: 96; public on 14 Feb 2023
31 Mar 2023 report: 82; public on 15 May 2023
30 Jun 2023 report: 72; public on 14 Aug 2023
30 Sep 2023 report: 70; public on 14 Nov 2023
31 Dec 2023 report: 63; public on 14 Feb 2024
31 Mar 2024 report: 43; public on 15 May 2024
30 Jun 2024 report: 45; public on 14 Aug 2024
30 Sep 2024 report: 48; public on 14 Nov 2024
31 Dec 2024 report: 55; public on 14 Feb 2025
31 Mar 2025 report: 47; public on 15 May 2025
30 Jun 2025 report: 47; public on 14 Aug 2025
30 Sep 2025 report: 54; public on 14 Nov 2025
31 Dec 2025 report: 66; public on 17 Feb 2026
31 Mar 2026 report: 77; public on 15 May 2026
30 Jun 2026 report: 95; public on 14 Aug 2026
30 Sep 2026 report: 108; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 2.4M shares sold short in the 14 Aug 2026 report, 2.0× the same report last year.
  • Short interest spike: had 2.9M shares sold short in the 31 Jul 2026 report, 2.3× the same report last year Public on 12 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $396K in the last 12 months (the 12 months before: -$213K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 97 insider trades

Last 90 days: 1 sale, $28K; 3 purchases, $30K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Dario ScimecaChief Legal OfficerSellplanned in advance (10b5-1)2,821$9.75$28KForm 4
30 Sep 2026Stanley FrankelDirectorBuy1,000$6.00$6KForm 4
29 Sep 2026Melinda BrownDirectorBuy1,135$6.27$7KForm 4
29 Sep 2026Geno J GermanoDirectorBuy2,609$6.28$16KForm 4
19 Feb 2026Michael AmorosoPresident and CEOSellplanned in advance (10b5-1); after exercising options20,559$3.84$79KForm 4
19 Feb 2026John Alexander KellyChief Financial OfficerSellplanned in advance (10b5-1); after exercising options8,149$3.84$31KForm 4
19 Feb 2026J. Jefferson SmithChief Research OfficerSellplanned in advance (10b5-1); after exercising options4,925$3.84$19KForm 4
19 Feb 2026Dario ScimecaGeneral Counsel and SecretarySellplanned in advance (10b5-1); after exercising options4,925$3.84$19KForm 4

108 institutions reported shares at the end of Q3 2026, 70% of the shares outstanding; 20 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Lynx1 Capital Management LP2.8M9.87%$17.3M+1.8M+190%
Aberdeen Group plc2.2M7.98%$14.0MNo change
Bleichroeder LP2.0M7.22%$12.6MNo change
BlackRock, Inc.1.6M5.75%$10.1M+434K+37%
Boothbay Fund Management, LLC1.3M4.82%$8.4MNo change
Vanguard Capital Management LLC1.1M3.95%$6.9M-13K-1.2%
Driehaus Capital Management LLC947K3.39%$5.9MNo change
Parkman Healthcare Partners LLC837K3.00%$5.2MNew+837K
Affinity Asset Advisors, LLC647K2.31%$4.0MNo change
Geode Capital Management, LLC634K2.27%$4.0M+13K+2.1%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 16 Dec 2010. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
16 Dec 2010Department of CommerceNational Institute of Standards and Technology$2.7Mup to $5.6MGENETIC ENGINEERING OF ELITE BIOPRODUCTION CELL LINESGrantUSAspending

Company events

All 48 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
27 Jul 2026Director or officer change8-K
16 Jun 2026Signed a major agreementSame filing: took on new debt8-K
26 May 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
2 Sep 2025Director or officer change8-K
7 Mar 2025Director or officer change8-K
29 Jan 2025Director or officer change8-K
12 Sep 2024Director or officer change8-K
10 Jun 2024Director or officer changeSame filing: shareholder vote results8-K

The 5 newest of 105 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 May 2021confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Precision BioSciences (DTIL): had 6.4M shares sold short in the 15 Apr 2021 report, 3.7× the same report last year, while it reported revenue of $16.3M for the quarter ended 31 Mar 2021, 2.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 27 Apr 2021
  • Financials: Quarterly revenue change, became public on 18 May 2021
2020-04-15: 1.7M2020-04-30: 1.9M2020-05-15: 1.6M2020-05-29: 1.6M2020-06-15: 1.7M2020-06-30: 2.3M2020-07-15: 2.0M2020-07-31: 1.9M2020-08-14: 1.9M2020-08-31: 1.7M2020-09-15: 2.2M2020-09-30: 2.8M2020-10-15: 2.8M2020-10-30: 2.7M2020-11-13: 2.4M2020-11-30: 2.1M2020-12-15: 2.8M2020-12-31: 4.2M2021-01-15: 3.9M2021-01-29: 3.6M2021-02-12: 3.4M2021-02-26: 3.4M2021-03-15: 3.5M2021-03-31: 6.0M2021-04-15: 6.4M
The 15 Apr 2021 report against the 24 reports before it. this reportearliernormal: 2.4M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 27 Apr 2021

Precision BioSciences had 6.4M shares sold short in the 15 Apr 2021 report, 3.7× the same report last year.

This period
6.4M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
554K
How far from its usual level
+4.9
Same report last year
1.7M
History used
731 days
2020-04-15: 1.7M2020-04-30: 1.9M2020-05-15: 1.6M2020-05-29: 1.6M2020-06-15: 1.7M2020-06-30: 2.3M2020-07-15: 2.0M2020-07-31: 1.9M2020-08-14: 1.9M2020-08-31: 1.7M2020-09-15: 2.2M2020-09-30: 2.8M2020-10-15: 2.8M2020-10-30: 2.7M2020-11-13: 2.4M2020-11-30: 2.1M2020-12-15: 2.8M2020-12-31: 4.2M2021-01-15: 3.9M2021-01-29: 3.6M2021-02-12: 3.4M2021-02-26: 3.4M2021-03-15: 3.5M2021-03-31: 6.0M2021-04-15: 6.4M
the 15 Apr 2021 report24 earlier reportsnormal: 2.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 18 May 2021

Precision BioSciences reported revenue of $16.3M for the quarter ended 31 Mar 2021, 2.3× the same quarter last year.

This period
$16.3M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$6.0M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+6.6
Same quarter last year
$7.0M
History used
1,096 days
2019-03-31: $5.5M2019-06-30: $5.4M2019-09-30: $4.9M2019-12-31: $6.5M2020-03-31: $7.0M2020-06-30: $1.1M2020-09-30: $7.4M2020-12-31: $8.8M2021-03-31: $16.3M
the quarter ended 31 Mar 20218 earlier quartersnormal: $6.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 1 Oct 2026Insiders record

    Frankel Stanley (director) bought 1,000 shares of DTIL ($6,000) (dated 30 Sep 2026)

  2. 30 Sep 2026Insiders record

    Brown Melinda (director) bought 1,135 shares of DTIL ($7,116) (dated 29 Sep 2026)

  3. 30 Sep 2026Insiders record

    Germano Geno J (director) bought 2,609 shares of DTIL ($16,385) (dated 29 Sep 2026)

  4. 26 Aug 2026Short interest and volume change

    had 2.4M shares sold short in the 14 Aug 2026 report, 2.0× the same report last year.

    Same report last year: 1.2M; its normal report is 1.3M.

    See the evidence
    This period
    2.4M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    187K
    How far from its usual level
    +4.0
    Same report last year
    1.2M
    History used
    2,678 days
    2025-08-15: 1.2M2025-08-29: 1.1M2025-09-15: 1.2M2025-09-30: 1.1M2025-10-15: 464K2025-10-31: 486K2025-11-14: 533K2025-11-28: 637K2025-12-15: 811K2025-12-31: 1.1M2026-01-15: 1.3M2026-01-30: 1.4M2026-02-13: 1.5M2026-02-27: 1.4M2026-03-13: 1.4M2026-03-31: 1.2M2026-04-15: 1.2M2026-04-30: 1.4M2026-05-15: 1.5M2026-05-29: 1.7M2026-06-15: 1.9M2026-06-30: 2.3M2026-07-15: 2.4M2026-07-31: 2.9M2026-08-14: 2.4M
    the 14 Aug 2026 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 12 Aug 2026Short interest and volume change

    had 2.9M shares sold short in the 31 Jul 2026 report, 2.3× the same report last year.

    Same report last year: 1.3M; its normal report is 1.3M.

    See the evidence
    This period
    2.9M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +7.2
    Same report last year
    1.3M
    History used
    2,664 days
    2025-07-31: 1.3M2025-08-15: 1.2M2025-08-29: 1.1M2025-09-15: 1.2M2025-09-30: 1.1M2025-10-15: 464K2025-10-31: 486K2025-11-14: 533K2025-11-28: 637K2025-12-15: 811K2025-12-31: 1.1M2026-01-15: 1.3M2026-01-30: 1.4M2026-02-13: 1.5M2026-02-27: 1.4M2026-03-13: 1.4M2026-03-31: 1.2M2026-04-15: 1.2M2026-04-30: 1.4M2026-05-15: 1.5M2026-05-29: 1.7M2026-06-15: 1.9M2026-06-30: 2.3M2026-07-15: 2.4M2026-07-31: 2.9M
    the 31 Jul 2026 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 27 Jul 2026Filings record

    Director or officer change

  7. 26 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 26 May 2026Filings record

    Director or officer change

  9. 7 May 2026Financials change

    reported revenue of $10.8M for the quarter ended 31 Mar 2026, 374× the same quarter last year.

    Same quarter last year: $29K; its normal quarter is $607K.

    See the evidence
    This period
    $10.8M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $607K
    Typical spread (median absolute deviation)
    $592K
    How far from its usual level
    +10.2
    Same quarter last year
    $29K
    History used
    2,922 days
    2024-03-31: $17.6M2024-06-30: $49.9M2024-09-30: $576K2024-12-31: $638K2025-03-31: $29K2025-06-30: $18K2025-09-30: $13K2025-12-31: $34.2M2026-03-31: $10.8M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $607K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  10. 19 Mar 2026Financials change

    reported revenue of $34.2M for the quarter ended 31 Dec 2025, 54× the same quarter last year.

    Same quarter last year: $638K; its normal quarter is $607K.

    See the evidence
    This period
    $34.2M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $607K
    Typical spread (median absolute deviation)
    $592K
    How far from its usual level
    +33.6
    Same quarter last year
    $638K
    History used
    2,832 days
    2023-12-31: $7.0M2024-03-31: $17.6M2024-06-30: $49.9M2024-09-30: $576K2024-12-31: $638K2025-03-31: $29K2025-06-30: $18K2025-09-30: $13K2025-12-31: $34.2M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $607K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 18 Dec 2025Insiders record

    Frankel Stanley (director) bought 2,700 shares of DTIL ($12,690) (dated 17 Dec 2025)

  12. 18 Dec 2025Insiders record

    Germano Geno J (director) bought 3,000 shares of DTIL ($14,160) (dated 17 Dec 2025)

  13. 18 Dec 2025Insiders record

    Brown Melinda (director) bought 1,381 shares of DTIL ($6,864) (dated 17 Dec 2025)

  14. 1 Oct 2025Insiders record

    Frankel Stanley (director) bought 2,700 shares of DTIL ($13,419) (dated 30 Sep 2025)

  15. 25 Sep 2025Insiders record

    Brown Melinda (director) bought 1,400 shares of DTIL ($6,846) (dated 24 Sep 2025)

  16. 2 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 2 Sep 2025Filings record

    Director or officer change

  18. 28 Jun 2025Insiders record

    Brown Melinda (director) bought 1,682 shares of DTIL ($6,963) (dated 27 Jun 2025)

  19. 28 Jun 2025Insiders record

    Buehler Kevin (director) bought 5,076 shares of DTIL ($21,116) (dated 27 Jun 2025)

  20. 10 May 2025Short interest and volume change

    had 667K shares sold short in the 30 Apr 2025 report, 2.0× the same report last year.

    Same report last year: 336K; its normal report is 302K.

    See the evidence
    This period
    667K (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    302K
    Typical spread (median absolute deviation)
    64K
    How far from its usual level
    +3.8
    Same report last year
    336K
    History used
    2,207 days
    2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K2025-02-14: 775K2025-02-28: 737K2025-03-14: 618K2025-03-31: 753K2025-04-15: 652K2025-04-30: 667K
    the 30 Apr 2025 report24 earlier reportsnormal: 302K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 26 Apr 2025Short interest and volume change

    had 652K shares sold short in the 15 Apr 2025 report, 1.9× the same report last year.

    Same report last year: 350K; its normal report is 302K.

    See the evidence
    This period
    652K (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    302K
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +4.2
    Same report last year
    350K
    History used
    2,192 days
    2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K2025-02-14: 775K2025-02-28: 737K2025-03-14: 618K2025-03-31: 753K2025-04-15: 652K
    the 15 Apr 2025 report24 earlier reportsnormal: 302K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 10 Apr 2025Short interest and volume change

    had 753K shares sold short in the 31 Mar 2025 report, 2.6× the same report last year.

    Same report last year: 289K; its normal report is 293K.

    See the evidence
    This period
    753K (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +5.9
    Same report last year
    289K
    History used
    2,177 days
    2024-03-28: 289K2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K2025-02-14: 775K2025-02-28: 737K2025-03-14: 618K2025-03-31: 753K
    the 31 Mar 2025 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 29 Mar 2025Insiders record

    Buehler Kevin (director) bought 4,523 shares of DTIL ($21,122) (dated 28 Mar 2025)

  24. 29 Mar 2025Insiders record

    Brown Melinda (director) bought 1,839 shares of DTIL ($8,735) (dated 28 Mar 2025)

  25. 28 Mar 2025Insiders record

    Germano Geno J (director) bought 3,250 shares of DTIL ($17,225) (dated 27 Mar 2025)

  26. 26 Mar 2025Short interest and volume change

    had 618K shares sold short in the 14 Mar 2025 report, 3.5× the same report last year.

    Same report last year: 178K; its normal report is 282K.

    See the evidence
    This period
    618K (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    282K
    Typical spread (median absolute deviation)
    51K
    How far from its usual level
    +4.5
    Same report last year
    178K
    History used
    2,160 days
    2024-03-15: 178K2024-03-28: 289K2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K2025-02-14: 775K2025-02-28: 737K2025-03-14: 618K
    the 14 Mar 2025 report24 earlier reportsnormal: 282K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 12 Mar 2025Short interest and volume change

    had 737K shares sold short in the 28 Feb 2025 report, 15× the same report last year.

    Same report last year: 49K; its normal report is 275K.

    See the evidence
    This period
    737K (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    275K
    Typical spread (median absolute deviation)
    49K
    How far from its usual level
    +6.3
    Same report last year
    49K
    History used
    2,146 days
    2024-02-29: 49K2024-03-15: 178K2024-03-28: 289K2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K2025-02-14: 775K2025-02-28: 737K
    the 28 Feb 2025 report24 earlier reportsnormal: 275K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 7 Mar 2025Filings record

    Director or officer change

  29. 27 Feb 2025Short interest and volume change

    had 775K shares sold short in the 14 Feb 2025 report, 19× the same report last year.

    Same report last year: 40K; its normal report is 272K.

    See the evidence
    This period
    775K (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    272K
    Typical spread (median absolute deviation)
    46K
    How far from its usual level
    +7.4
    Same report last year
    40K
    History used
    2,132 days
    2024-02-15: 40K2024-02-29: 49K2024-03-15: 178K2024-03-28: 289K2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K2025-02-14: 775K
    the 14 Feb 2025 report24 earlier reportsnormal: 272K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 12 Feb 2025Short interest and volume change

    had 757K shares sold short in the 31 Jan 2025 report, 54% below the same report last year.

    Same report last year: 1.7M; its normal report is 272K.

    See the evidence
    This period
    757K (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    272K
    Typical spread (median absolute deviation)
    46K
    How far from its usual level
    +7.1
    Same report last year
    1.7M
    History used
    2,118 days
    2024-01-31: 1.7M2024-02-15: 40K2024-02-29: 49K2024-03-15: 178K2024-03-28: 289K2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K2025-01-31: 757K
    the 31 Jan 2025 report24 earlier reportsnormal: 272K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 29 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 29 Jan 2025Filings record

    Director or officer change

  33. 28 Jan 2025Short interest and volume change

    had 912K shares sold short in the 15 Jan 2025 report, 58% below the same report last year.

    Same report last year: 2.2M; its normal report is 272K.

    See the evidence
    This period
    912K (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    272K
    Typical spread (median absolute deviation)
    46K
    How far from its usual level
    +9.4
    Same report last year
    2.2M
    History used
    2,102 days
    2024-01-12: 2.2M2024-01-31: 1.7M2024-02-15: 40K2024-02-29: 49K2024-03-15: 178K2024-03-28: 289K2024-04-15: 350K2024-04-30: 336K2024-05-15: 344K2024-05-31: 345K2024-06-14: 307K2024-06-28: 297K2024-07-15: 276K2024-07-31: 252K2024-08-15: 255K2024-08-30: 235K2024-09-13: 234K2024-09-30: 218K2024-10-15: 214K2024-10-31: 215K2024-11-15: 240K2024-11-29: 269K2024-12-13: 274K2024-12-31: 307K2025-01-15: 912K
    the 15 Jan 2025 report24 earlier reportsnormal: 272K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 3 Jan 2025Insiders record

    Germano Geno J (director) bought 3,605 shares of DTIL ($16,186) (dated 2 Jan 2025)

  35. 1 Jan 2025Insiders record

    Kelly John Alexander (Chief Financial Officer) bought 2,113 shares of DTIL ($10,037) (dated 31 Dec 2024)

  36. 1 Jan 2025Insiders record

    Buehler Kevin (director) bought 4,320 shares of DTIL ($21,082) (dated 31 Dec 2024)

  37. 31 Dec 2024Insiders record

    Brown Melinda (director) bought 3,016 shares of DTIL ($13,723) (dated 30 Dec 2024)

  38. 22 Nov 2024Insiders record

    Kelly John Alexander (Chief Financial Officer) bought 3,000 shares of DTIL ($20,280) (dated 21 Nov 2024)

  39. 12 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 12 Sep 2024Filings record

    Director or officer change

Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.

Not listed: 193 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001357874
Ticker
DTIL
Domain
precisionbiosciences.com
Employer name
Precision BioSciences, Inc. (1 unverified)
Hq location
NC|DURHAM|27701 (1 unverified)
Name
a211subsidiariesofprecisio.htm, Document, EX-21.1, Precision BioSciences, Inc. and 1 more
Uei
NWW1HFV2RQU3
Wikidata
Q116056726
Wikipedia
Precision BioSciences
  • DOL H-1B labor condition applications and PERM certifications68 data points21 Oct 2019 to 24 Nov 2025
  • SEC Form 13F institutional holdings279 data points31 Mar 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)159 records8 Jun 2018 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)518 data points31 Dec 2017 to 29 Oct 2026
  • SEC Form 4 insider transactions97 records, 264 data points1 Apr 2019 to 12 Nov 2026
  • FINRA short interest (twice monthly)542 data points15 Apr 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3850 data points28 Mar 2019 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 18 data points12 Feb 2008 to 17 Dec 2012
  • Wikipedia pageviews1424 data points29 Dec 2022 to 21 Nov 2026